These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 28536803)

  • 1. Prospective multicenter phase II study of gemcitabine plus cisplatin in patients with unresectable gallbladder cancer.
    Hirooka Y; Ishikawa T; Kawashima H; Ohno E; Nonogaki K; Kanamori A; Hirai T; Uchida H; Shirai O; Ishikawa H; Goto H
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):119-125. PubMed ID: 28536803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer.
    Doval DC; Sekhon JS; Gupta SK; Fuloria J; Shukla VK; Gupta S; Awasthy BS
    Br J Cancer; 2004 Apr; 90(8):1516-20. PubMed ID: 15083178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modified gemcitabine and oxaliplatin or gemcitabine + cisplatin in unresectable gallbladder cancer: Results of a phase III randomised controlled trial.
    Sharma A; Kalyan Mohanti B; Pal Chaudhary S; Sreenivas V; Kumar Sahoo R; Kumar Shukla N; Thulkar S; Pal S; Deo SV; Pathy S; Ranjan Dash N; Kumar S; Bhatnagar S; Kumar R; Mishra S; Sahni P; Iyer VK; Raina V
    Eur J Cancer; 2019 Dec; 123():162-170. PubMed ID: 31707181
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic outcomes and prognostic factors in unresectable gallbladder cancer treated with gemcitabine plus cisplatin.
    You MS; Ryu JK; Choi YH; Choi JH; Huh G; Paik WH; Lee SH; Kim YT
    BMC Cancer; 2019 Jan; 19(1):10. PubMed ID: 30611225
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin.
    Dierks J; Gaspersz MP; Belkouz A; van Vugt JLA; Coelen RJS; de Groot JWB; Ten Tije AJ; Meijer WG; Pruijt JFM; van Voorthuizen T; van Spronsen DJ; Rentinck M; Ten Oever D; Smit JM; Otten HM; van Gulik TM; Wilmink JW; Groot Koerkamp B; Klümpen H
    Acta Oncol; 2018 Jun; 57(6):807-812. PubMed ID: 29265948
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma.
    Thongprasert S; Napapan S; Charoentum C; Moonprakan S
    Ann Oncol; 2005 Feb; 16(2):279-81. PubMed ID: 15668284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and biomarker analysis of nivolumab plus gemcitabine and cisplatin in patients with unresectable or metastatic biliary tract cancers: results from a phase II study.
    Feng K; Liu Y; Zhao Y; Yang Q; Dong L; Liu J; Li X; Zhao Z; Mei Q; Han W
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32487569
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase II study of gemcitabine and oxaliplatin (Oxigem) in unresectable gall bladder cancer.
    Sharma A; Mohanti B; Raina V; Shukla N; Pal S; Dwary A; Deo S; Sahni P; Garg P; Thulkar S; DattaGupta S; Rath G
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):497-502. PubMed ID: 19575200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gemcitabine and cisplatin for inoperable and/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM).
    Giuliani F; Gebbia V; Maiello E; Borsellino N; Bajardi E; Colucci G;
    Ann Oncol; 2006 Jun; 17 Suppl 7():vii73-7. PubMed ID: 16760299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nivolumab alone or in combination with cisplatin plus gemcitabine in Japanese patients with unresectable or recurrent biliary tract cancer: a non-randomised, multicentre, open-label, phase 1 study.
    Ueno M; Ikeda M; Morizane C; Kobayashi S; Ohno I; Kondo S; Okano N; Kimura K; Asada S; Namba Y; Okusaka T; Furuse J
    Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):611-621. PubMed ID: 31109808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gemcitabine and Cisplatin is a highly effective combination chemotherapy in patients with advanced cancer of the gallbladder.
    Malik IA; Aziz Z; Zaidi SH; Sethuraman G
    Am J Clin Oncol; 2003 Apr; 26(2):174-7. PubMed ID: 12714891
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gemcitabine-based versus fluoropyrimidine-based chemotherapy with or without platinum in unresectable biliary tract cancer: a retrospective study.
    Kim MJ; Oh DY; Lee SH; Kim DW; Im SA; Kim TY; Heo DS; Bang YJ
    BMC Cancer; 2008 Dec; 8():374. PubMed ID: 19091129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma - a retrospective study.
    Croitoru A; Gramaticu I; Dinu I; Gheorghe L; Alexandrescu S; Buica F; Luca I; Becheanu G; Herlea V; Simionov I; Hrehoret D; Lupescu I; Popescu I; Diculescu M
    J Gastrointestin Liver Dis; 2012 Sep; 21(3):277-84. PubMed ID: 23012669
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A pilot study of concurrent chemoradiotherapy with gemcitabine and cisplatin in patients with locally advanced biliary tract cancer.
    Lee KJ; Yi SW; Cha J; Seong J; Bang S; Song SY; Kim HM; Park SW
    Cancer Chemother Pharmacol; 2016 Oct; 78(4):841-6. PubMed ID: 27586966
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Retroperitoneal Lymphadenopathy (RPLN) on the Outcomes of Locally Advanced Gall Bladder Cancer (GBC) Following Chemotherapy (CT) or Chemotherapy Followed by Consolidation Chemoradiotherapy (CTRT).
    Agrawal S; Naik N; Priyanka P
    J Gastrointest Cancer; 2024 Oct; 56(1):7. PubMed ID: 39425807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
    Moehler M; Maderer A; Schimanski C; Kanzler S; Denzer U; Kolligs FT; Ebert MP; Distelrath A; Geissler M; Trojan J; Schütz M; Berie L; Sauvigny C; Lammert F; Lohse A; Dollinger MM; Lindig U; Duerr EM; Lubomierski N; Zimmermann S; Wachtlin D; Kaiser AK; Schadmand-Fischer S; Galle PR; Woerns M;
    Eur J Cancer; 2014 Dec; 50(18):3125-35. PubMed ID: 25446376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A prospective randomized controlled clinical trial of irinotecan plus cisplatin versus gemcitabine plus cisplatin as a first-line treatment for advanced non-small cell lung cancer].
    Zhao WY; Chen DY
    Zhonghua Zhong Liu Za Zhi; 2012 Oct; 34(10):775-9. PubMed ID: 23291073
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75.
    Hahn NM; Stadler WM; Zon RT; Waterhouse D; Picus J; Nattam S; Johnson CS; Perkins SM; Waddell MJ; Sweeney CJ;
    J Clin Oncol; 2011 Apr; 29(12):1525-30. PubMed ID: 21422406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
    Tan ES; Cao B; Kim J; Al-Toubah TE; Mehta R; Centeno BA; Kim RD
    Cancer; 2021 Apr; 127(8):1293-1300. PubMed ID: 33289918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.